University of North Carolina School of Medicine

Research institutionUnited Statesmed.unc.edu

The University of North Carolina School of Medicine, part of the University of North Carolina at Chapel Hill, is a leading institution for medical education, research, and patient care in the United States. Established as one of the oldest medical schools in the country, it focuses on training the next generation of healthcare professionals while advancing scientific discovery in various medical fields.

Read more

The school conducts extensive research in areas including cancer, cardiovascular diseases, neuroscience, and infectious diseases. It participates in numerous clinical trials and collaborates with pharmaceutical companies and other research entities to develop new treatments and therapies. Its faculty and students contribute to publications in top medical journals and hold positions in national medical organizations.

Located in Chapel Hill, North Carolina, the institution operates through multiple departments and centers, with strong ties to the UNC Health Care system. As a public research university component, it receives funding from state appropriations, federal grants such as those from the National Institutes of Health, and private donations. The school is known for its commitment to diversity, community health initiatives, and addressing health disparities in the region and beyond.

In the broader medical industry, the University of North Carolina School of Medicine ranks among the top public medical schools, emphasizing innovation in medical education and translational research that bridges laboratory findings to clinical applications.

Also known as University of North Carolina at Chapel Hill School of Medicine.

Projects UNC School of Medicine is involved in

None yet. When a new project in the record names UNC School of Medicine as owner, partner or investor, it shows here.

Active projects close to UNC School of Medicine

UNC School of Medicine in chemical industry news

20 October 2026
Amgen and AstraZeneca: TEZSPIRE shows histologic, symptom and endoscopic remission in EoE (CROSSING)

Phase 3 CROSSING found TEZSPIRE produced sustained histologic remission, reduced dysphagia scores and achieved endoscopic remission through week 52 in adolescents and adults with eosinophilic esophagitis.